Imatinib Remedica (Imatinib)

Imatinib is a targeted antineoplastic agent that interferes with specific tyrosine‑kinase driven cancers.

• Chronic myeloid leukemia (CML): suppresses BCR‑ABL driven leukemic proliferation and prolongs survival.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): inhibits malignant lymphoblast growth and supports remission.
• Gastrointestinal stromal tumor (GIST): blocks c‑KIT signaling to reduce tumor size and delay progression.

• Imatinib binds to the ATP‑binding pocket of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, preventing phosphorylation of downstream substrates. This inhibition halts signal transduction pathways that drive uncontrolled cell division, leading to apoptosis of malignant cells while sparing most normal tissues.

Adverse reactions may occur with Imatinib therapy and are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Edema: peripheral swelling, especially around the ankles.
• Fatigue: generalized tiredness affecting daily activities.
• Diarrhea: loose stools that may be intermittent.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or jaundice requiring monitoring.
• Cardiotoxicity: rare cases of heart failure or reduced ejection fraction.
• Severe neutropenia: marked drop in white blood cells increasing infection risk.
• Hemorrhagic events: uncommon bleeding complications.

Before initiating therapy, clinicians should assess baseline organ function and monitor patients regularly.

• Baseline labs: obtain complete blood count, liver and renal function tests.
• Hepatic monitoring: repeat liver enzymes periodically, adjust if significant elevation occurs.
• Cardiac assessment: evaluate cardiac history; monitor for signs of heart failure.
• Drug interactions: review concomitant medications for CYP3A4 inhibitors or inducers.
• Pregnancy and lactation: avoid use unless benefits outweigh potential risks.
• Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture and direct sunlight.

Imatinib can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels and toxicity.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness.
• Antacids containing aluminum or magnesium: can decrease absorption if taken simultaneously.

Moderate Interactions (Monitor Closely)

• Proton pump inhibitors: may modestly reduce bioavailability; consider timing separation.
• Warfarin: monitor INR closely as Imatinib can enhance anticoagulant effect.
• Vaccines: live attenuated vaccines should be avoided during treatment.